Research Article
Clinical Characteristics and Early Interventional Responses in Patients with Severe COVID-19 Pneumonia
Table 4
Treatment of patients infected with COVID-19.
| | (%) | Median (IQR) |
| | No. of patients | 37 | 37 | | Oxygen therapy | | Nasal cannula | 32 (86%) | NA | | High-flow nasal cannula | 5 (14%) | NA | | Antiviral treatment | NA | | α-Interferon | 37 (100%) | NA | | Lopinavir/litonavir | 37 (100%) | NA | | Arbidol | 23 (62%) | NA | | Glucocorticoids | 30 (81%) | 7 (4-11) | | Intravenous immunoglobulin therapy | 25 (68%) | 4 (3-5.5) | | Antibiotic treatment | 9 (24%) | 7 (4.5-7.5) |
|
|
Data are median (IQR) or (%), where is the total number of patients with available data. |
